Welcome to the Shroomery Message Board! You are experiencing a small sample of what the site has to offer. Please login or register to post messages and view our exclusive members-only content. You'll gain access to additional forums, file attachments, board customizations, encrypted private messages, and much more!
NEW YORK, Aug 18 (Reuters) - Vicuron Pharmaceuticals Inc. (MICU.O: Quote, Profile, Research), which is being acquired by Pfizer (PFE.N: Quote, Profile, Research), on Thursday said it filed an application with U.S. regulators for a new medication to treat the most common hospital-acquired fungal infection.
Vicuron said its application to the U.S. Food and Drug Administration includes clinical data from a previously announced Phase 3 trial showing the superiority of its drug anidulafungin in treating a fungal condition versus the commonly prescribed fluconazole.
Kira: What do Klingons dream about?
Worf: Things that would send cold chills down your spine, and wake you up in the middle of the night. No, it is better you do not know